Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

3(33.3%)

9Total

Phase 1(6)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07328529Phase 2Not Yet Recruiting

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Role: lead

NCT02055638Phase 1Completed

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

Role: lead

NCT02507284Phase 2Completed

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

Role: lead

NCT02733614Phase 2Terminated

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

Role: lead

NCT02922166Phase 1Unknown

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Role: lead

NCT01088932Phase 1Completed

Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

Role: lead

NCT00910455Phase 1Completed

Study of SRX246 Capsules in Healthy Adult Volunteers

Role: lead

NCT00461370Phase 1Completed

Safety Study of SRX251 Capsules in Healthy Female Volunteers

Role: lead

NCT00532467Phase 1Completed

Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers

Role: lead

All 9 trials loaded